Latest news and press releases about Silo Pharma, Inc. (SILO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems.
Price
| Price | $1.76 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.39 |
| EV / EBITDA | 0.12 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -81.74% |
| Return on Invested Capital | -91.31% |
| Return on Assets | -75.13% |
| Gross Margin | -474.31% |
| Operating Margin | -8250.46% |
| Net Margin | -8269.53% |
Related companies: BDRX · CANF · CMND · CNSP · GRI · INM · JAGX
Explore sector: Healthcare · Biotechnology
More sections of SILO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks